drugset
drugset / Trial / NCT01680796

Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma

NCT01680796 ↗

Phase 1 Withdrawn University of Florida Novartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label phase I study in which dovitinib is given in combination with bortezomib and dexamethasone. Dovitinib dose escalation is planned in order to determine its maximum tolerated dose when given in this combination.

Timeline

Start
2013-02
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dovitinib Small molecule 200 mg Oral
Subject Dovitinib Small molecule 300 mg Oral
Subject Dovitinib Small molecule 400 mg Oral
Subject Dovitinib Small molecule 500 mg Oral
Background Bortezomib Small molecule 1.3 mg/m2 Intravenous
Background Bortezomib Small molecule 1.6 mg/m2 Intravenous
Background Dexamethasone Small molecule 20 mg Oral

Indications

plasma cell myeloma